Document is current
Any future updates will be listed below
-
Authors
van der Woude, Lieke L https://orcid.org/0000-0002-4761-0768
Gorris, Mark A J https://orcid.org/0000-0003-3621-226X
Wortel, Inge M N
Creemers, Jeroen H A https://orcid.org/0000-0003-0371-8416
Verrijp, Kiek https://orcid.org/0000-0001-5223-8406
Monkhorst, Kim
Grünberg, Katrien
van den Heuvel, Michel M
Textor, Johannes https://orcid.org/0000-0002-0459-9458
Figdor, Carl G https://orcid.org/0000-0002-2366-9212
Piet, Berber
Theelen, Willemijn S M E
de Vries, I Jolanda M https://orcid.org/0000-0002-8653-4040
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02492568 at ClinicalTrials.govnct02492568 at ClinicalTrials.govDocuments that mention this clinical trial
34 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes
https://doi.org/10.1136/jitc-2024-sitc2024.0034
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
https://doi.org/10.1136/jitc-2022-005248
nct02492568 at ClinicalTrials.govDocuments that mention this clinical trial
34 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes
https://doi.org/10.1136/jitc-2024-sitc2024.0034
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
https://doi.org/10.1136/jitc-2022-005248
nct02492568 at ClinicalTrials.govDocuments that mention this clinical trial
34 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes
https://doi.org/10.1136/jitc-2024-sitc2024.0034
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
https://doi.org/10.1136/jitc-2022-005248
Documents that mention this clinical trial
34 Monitoring response to immunotherapy in lung cancer using cell-free DNA fragmentomes
https://doi.org/10.1136/jitc-2024-sitc2024.0034
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
https://doi.org/10.1136/jitc-2022-005248
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (10673)
Merck Sharp & Dohme (N/A)
- License Information
